Ultragenyx Files 2025 Proxy Statement
Ticker: RARE · Form: DEF 14A · Filed: Mar 28, 2025 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | DEF 14A |
| Filed Date | Mar 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: RARE
TL;DR
Proxy statement filed for Ultragenyx (RARE) - shareholders vote on exec pay & board.
AI Summary
Ultragenyx Pharmaceutical Inc. filed its DEF 14A proxy statement on March 28, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, board of directors, and other corporate governance matters. Key information includes compensation details for named executive officers and proposals to be voted on at the upcoming annual meeting.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation and corporate governance, enabling informed voting decisions on matters affecting the company's direction and shareholder value.
Risk Assessment
Risk Level: medium — Proxy statements often contain information about executive compensation and corporate governance that can influence investor sentiment and stock performance.
Key Numbers
- 2024 — Fiscal Year End (The filing covers the fiscal year ending December 31, 2024.)
- 20250328 — Filing Date (The definitive proxy statement was filed on this date.)
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Filer of the DEF 14A
- 0001308179-25-000296 (filing_id) — Accession number for the filing
- 20250328 (date) — Filing date
- 20250515 (date) — Period of report
- 0001515673 (company_id) — Central Index Key for Ultragenyx
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used to solicit proxies from shareholders and provides detailed information about matters to be voted on at a company's annual or special meeting, including executive compensation, director elections, and other corporate governance issues.
When is the period of report for this Ultragenyx filing?
The period of report for this Ultragenyx DEF 14A filing is May 15, 2025.
What is Ultragenyx Pharmaceutical Inc.'s Central Index Key (CIK)?
Ultragenyx Pharmaceutical Inc.'s Central Index Key (CIK) is 0001515673.
What is the business address of Ultragenyx Pharmaceutical Inc.?
The business address of Ultragenyx Pharmaceutical Inc. is 60 LEVERONI COURT, NOVATO, CA 94949.
What is the SIC code for Ultragenyx Pharmaceutical Inc.?
The Standard Industrial Classification (SIC) code for Ultragenyx Pharmaceutical Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 28, 2025 regarding Ultragenyx Pharmaceutical Inc. (RARE).